Overview

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

This study is to determine the safety and Pharmacokinetics (PK) and Pharmacodynamics (PD) of INH-08189 dosed once a day (QD), two times a day (BID) or adjunctively with Ribavirin and a study of the food effect in Chronically-infected Genotype 1 Hepatitis C Virus (HCV), Treatment-naïve subjects.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Ribavirin